Israel's largest healthcare provider reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.
"It shows unequivocally that Pfizer's coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study," said Ran Balicer, Clalit's chief innovation officer.
He added that the data indicates the Pfizer vaccine, is even more effective two weeks or more after the second shot.
Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated - aged 60 or older.
Hospitalisation and serious illness were still rising in younger groups who began vaccinations weeks later.
Hospitalisation and serious illness were still rising in younger groups who began vaccinations weeks later.
No comments:
Post a Comment